Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.

Funda Meric-Bernstam Antoine Hollebecque Junji Furuse Do Youn Oh John A Bridgewater Masashi Shimura Bailey Anderson Nanae Hangai Volker Wacheck Lipika Goyal

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Futibatinib showed a consistent and manageable safety profile across patients with various tumor types. AECIs were mostly reversible with appropriate clinical management.

Keyphrases

randomized controlled trial
emergency department
clinical trial
electronic health record